{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T18:54:35Z","timestamp":1767984875975,"version":"3.49.0"},"reference-count":77,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T00:00:00Z","timestamp":1689638400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["PD\/BDE\/150298\/2019"],"award-info":[{"award-number":["PD\/BDE\/150298\/2019"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Pharmaceutics"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.ijpharm.2023.123252","type":"journal-article","created":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T04:13:45Z","timestamp":1689826425000},"page":"123252","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Nasal-PAMPA: A novel non-cell-based high throughput screening assay for prediction of nasal drug permeability"],"prefix":"10.1016","volume":"643","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6390-6115","authenticated-orcid":false,"given":"Patr\u00edcia","family":"Henriques","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7500-1671","authenticated-orcid":false,"given":"Joana","family":"Bicker","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6726-5458","authenticated-orcid":false,"given":"Soraia","family":"Silva","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5607-0241","authenticated-orcid":false,"given":"Slavom\u00edra","family":"Doktorovov\u00e1","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6981-6639","authenticated-orcid":false,"given":"Ana","family":"Fortuna","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/j.ijpharm.2023.123252_b0005","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ejps.2013.08.029","article-title":"Bioavailability enhancement of verapamil HCl via intranasal chitosan microspheres","volume":"51","author":"Abdel Mouez","year":"2014","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2023.123252_b0010","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.addr.2017.09.020","article-title":"Chemical modification of drug molecules as strategy to reduce interactions with mucus","volume":"124","author":"Ara\u00fajo","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ijpharm.2023.123252_b0015","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s11095-015-1804-1","article-title":"Drug permeation characterization of inhaled dry powder formulations in air-liquid interfaced cell layer using an improved Simple Apparatus for Dispersion","volume":"33","author":"Asai","year":"2016","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ijpharm.2023.123252_b0020","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1517\/17425255.1.2.325","article-title":"The rise of PAMPA","volume":"1","author":"Avdeef","year":"2005","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.ijpharm.2023.123252_b0025","series-title":"Absorption and drug development: solubility, permeability, and charge state","author":"Avdeef","year":"2012"},{"key":"10.1016\/j.ijpharm.2023.123252_b0030","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ejps.2018.04.016","article-title":"Drug permeability profiling using cell-free permeation tools: Overview and applications","volume":"119","author":"Berben","year":"2018","journal-title":"Eur. J. Pharm. Sci."},{"issue":"Doc07","key":"10.1016\/j.ijpharm.2023.123252_b0035","article-title":"Physiology and pathophysiology of respiratory mucosa of the nose and the paranasal sinuses. GMS Curr Top Otorhinolaryngol","volume":"9","author":"Beule","year":"2010","journal-title":"Head Neck Surg."},{"key":"10.1016\/j.ijpharm.2023.123252_b0040","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/978-1-62703-758-7_12","article-title":"Principles and experimental considerations for in vitro transporter interaction assays","volume":"1113","author":"Bhoopathy","year":"2014","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ijpharm.2023.123252_b0045","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ijpharm.2016.01.074","article-title":"A new PAMPA model using an in-house brain lipid extract for screening the blood-brain barrier permeability of drug candidates","volume":"501","author":"Bicker","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2023.123252_b0050","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ejps.2004.11.010","article-title":"Fast-dissolving mucoadhesive microparticulate delivery system containing piroxicam","volume":"24","author":"Cilurzo","year":"2005","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2023.123252_b0055","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.antiviral.2011.09.012","article-title":"Brain distribution of ribavirin after intranasal administration","volume":"92","author":"Colombo","year":"2011","journal-title":"Antiviral Res."},{"key":"10.1016\/j.ijpharm.2023.123252_b0060","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ejps.2018.12.012","article-title":"Corneal-PAMPA: a novel, non-cell-based assay for prediction of corneal drug permeability","volume":"128","author":"Darg\u00f3","year":"2019","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2023.123252_b0065","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.tiv.2004.07.003","article-title":"The use of human nasal in vitro cell systems during drug discovery and development","volume":"19","author":"Dimova","year":"2005","journal-title":"Toxicol. In Vitro"},{"key":"10.1016\/j.ijpharm.2023.123252_b0070","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.carbpol.2014.02.064","article-title":"Nasal polysaccharides-glucose regulator microparticles: Optimization, tolerability and antidiabetic activity in rats","volume":"108","author":"Elmowafy","year":"2014","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.ijpharm.2023.123252_b0075","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ijpharm.2017.12.038","article-title":"Mucus-PVPA (mucus Phospholipid Vesicle-based Permeation Assay): an artificial permeability tool for drug screening and formulation development","volume":"537","author":"Falavigna","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2023.123252_b0080","doi-asserted-by":"crossref","first-page":"168","DOI":"10.3390\/pharmaceutics12020168","article-title":"Impact of mucin on drug diffusion: Development of a straightforward in vitro method for the determination of drug diffusivity in the presence of mucin","volume":"12","author":"Falavigna","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ijpharm.2023.123252_b0085","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.carbpol.2017.12.004","article-title":"Impact of HPMC on inhibiting crystallization and improving permeability of curcumin amorphous solid dispersions","volume":"181","author":"Fan","year":"2018","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.ijpharm.2023.123252_b0090","unstructured":"Food and Drug Administration. Inactive Ingredients Database FDA. https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/inactive-ingredients-database-download (2020)."},{"key":"10.1016\/j.ijpharm.2023.123252_b0095","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1002\/jps.22796","article-title":"Optimization of a parallel artificial membrane permeability assay for the fast and simultaneous prediction of human intestinal absorption and plasma protein binding of drug candidates: application to dibenz[b, f]azepine-5-carboxamide derivatives","volume":"101","author":"Fortuna","year":"2012","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2023.123252_b0100","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejpb.2014.03.004","article-title":"Intranasal delivery of systemic-acting drugs: small-molecules and biomacromolecules","volume":"88","author":"Fortuna","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ijpharm.2023.123252_b0105","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3390\/pharmaceutics12010079","article-title":"Comparison of various cell lines and three-dimensional mucociliary tissue model systems to estimate drug permeability using an in vitro transport study to predict nasal drug absorption in rats","volume":"12","author":"Furubayashi","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ijpharm.2023.123252_b0110","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1248\/bpb.24.1411","article-title":"Spray-dried powders as nasal absorption enhancers of cyanocobalamin","volume":"24","author":"Garc\u00eda-Arieta","year":"2001","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.ijpharm.2023.123252_b0115","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1080\/10717544.2018.1428242","article-title":"In vivo nose-to-brain delivery of the hydrophilic antiviral ribavirin by microparticle agglomerates","volume":"25","author":"Giuliani","year":"2018","journal-title":"Drug Deliv."},{"key":"10.1016\/j.ijpharm.2023.123252_b0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2020.105632","article-title":"Is intranasal administration an opportunity for direct brain delivery of lacosamide?","volume":"157","author":"Gon\u00e7alves","year":"2021","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2023.123252_b0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.120161","article-title":"A combo-strategy to improve brain delivery of antiepileptic drugs: focus on BCRP and intranasal administration","volume":"593","author":"Gon\u00e7alves","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2023.123252_b0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2016.09.086","article-title":"Application of RPMI 2650 as a cell model to evaluate solid formulations for intranasal delivery of drugs","volume":"515","author":"Gon\u00e7alves","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2023.123252_b0135","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.ejpb.2008.09.006","article-title":"The permeability of large molecular weight solutes following particle delivery to air-interfaced cells that model the respiratory mucosa","volume":"71","author":"Grainger","year":"2009","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ijpharm.2023.123252_b0140","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/bdd.2348","article-title":"In vitro and ex vivo experimental models for evaluation of intranasal systemic drug delivery as well as direct nose-to-brain drug delivery","volume":"44","author":"Haasbroek-Pheiffer","year":"2023","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.ijpharm.2023.123252_b0145","article-title":"Amorphous solid dispersions for nasal delivery: development, characterization and aerodynamic performance","volume":"360","author":"Henriques","year":"2020","journal-title":"AAPS PharmSci."},{"key":"10.1016\/j.ijpharm.2023.123252_b0150","first-page":"A7","article-title":"Benchmarking of particle engineering technologies for nasal powder manufacture","volume":"34","author":"Henriques","year":"2021","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.ijpharm.2023.123252_b0155","unstructured":"Henriques, P., Marques, J., Fortuna, A., Braga, M. & Costa, E. Spray-dried Microparticles vs. Chimeral Agglomerates for Nasal Powder Delivery: Characterization and Aerodynamic Performance. Respiratory Drug Delivery 3, 533\u2013538 (2020)."},{"key":"10.1016\/j.ijpharm.2023.123252_b0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejpb.2022.05.002","article-title":"Spray dried powders for nasal delivery: process and formulation considerations","volume":"176","author":"Henriques","year":"2022","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ijpharm.2023.123252_b0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2020.105667","article-title":"Co-amorphous formation of piroxicam-citric acid to generate supersaturation and improve skin permeation","volume":"158","author":"Hirakawa","year":"2021","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2023.123252_b0170","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0168-3659(02)00363-2","article-title":"Nasal drug delivery\u2014possibilities, problems and solutions","volume":"87","author":"Illum","year":"2003","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijpharm.2023.123252_b0175","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ejpb.2020.02.004","article-title":"Quantitative estimation of drug permeation through nasal mucosa using in vitro membrane permeability across Calu-3 cell layers for predicting in vivo bioavailability after intranasal administration to rats","volume":"149","author":"Inoue","year":"2020","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ijpharm.2023.123252_b0180","unstructured":"International Council For Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH guideline M10 on bioanalytical method validation and study sample analysis. https:\/\/www.ich.org\/page\/multidisciplinary-guidelines (2022)."},{"key":"10.1016\/j.ijpharm.2023.123252_b0185","unstructured":"ISO - ISO 10993-5:2009 - Biological evaluation of medical devices \u2014 Part 5: Tests for in vitro cytotoxicity. https:\/\/www.iso.org\/standard\/36406.html."},{"key":"10.1016\/j.ijpharm.2023.123252_b0190","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1080\/10837450802282462","article-title":"Preparation and evaluation of piroxicam\u2013HPMCAS solid dispersions for ocular use","volume":"13","author":"Jachowicz","year":"2008","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/j.ijpharm.2023.123252_b0195","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.3390\/pharmaceutics14102070","article-title":"Application of intranasal administration in the delivery of antidepressant active ingredients","volume":"14","author":"Jin","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ijpharm.2023.123252_b0200","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.jpba.2017.06.072","article-title":"An overview of in vitro dissolution\/release methods for novel mucosal drug delivery systems","volume":"147","author":"Jug","year":"2018","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.ijpharm.2023.123252_b0205","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.msec.2015.11.028","article-title":"PLGA\/DPPC\/trimethylchitosan spray-dried microparticles for the nasal delivery of ropinirole hydrochloride: in vitro, ex vivo and cytocompatibility assessment","volume":"59","author":"Karavasili","year":"2016","journal-title":"Mater. Sci. Eng. C"},{"key":"10.1016\/j.ijpharm.2023.123252_b0210","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/0005-2736(71)90301-4","article-title":"Isolation and some properties of plasma membranes from bovine olfactory epithelium","volume":"241","author":"Koyama","year":"1971","journal-title":"BBA - Biomembranes"},{"key":"10.1016\/j.ijpharm.2023.123252_b0215","article-title":"Pharmaceutical assessment of polyvinylpyrrolidone (PVP): as excipient from conventional to controlled delivery systems with a spotlight on COVID-19 inhibition","volume":"60","author":"Kurakula","year":"2020","journal-title":"J Drug Deliv Sci Technol"},{"key":"10.1016\/j.ijpharm.2023.123252_b0220","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.ijpharm.2017.09.018","article-title":"Physicochemical properties of mucus and their impact on transmucosal drug delivery","volume":"532","author":"Leal","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2023.123252_b0225","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s11745-010-3432-1","article-title":"Lipidomic analysis of porcine olfactory epithelial membranes and cilia","volume":"45","author":"Lobasso","year":"2010","journal-title":"Lipids"},{"key":"10.1016\/j.ijpharm.2023.123252_b0230","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ejps.2012.10.005","article-title":"Solid-state dependent dissolution and oral bioavailability of piroxicam in rats","volume":"48","author":"Lust","year":"2013","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2023.123252_b0235","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.ijpharm.2015.03.079","article-title":"Amorphous solid dispersions of piroxicam and Soluplus\u00ae: qualitative and quantitative analysis of piroxicam recrystallization during storage","volume":"486","author":"Lust","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2023.123252_b0240","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1211\/jpp.61.07.0007","article-title":"An improved primary human nasal cell culture for the simultaneous determination of transepithelial transport and ciliary beat frequency","volume":"61","author":"Mallants","year":"2009","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ijpharm.2023.123252_b0245","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.jconrel.2020.05.045","article-title":"Hypromellose \u2013 A traditional pharmaceutical excipient with modern applications in oral and oromucosal drug delivery","volume":"324","author":"Ma\u0161kov\u00e1","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijpharm.2023.123252_b0250","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s13318-017-0426-x","article-title":"Is RPMI 2650 a suitable in vitro nasal model for drug transport studies?","volume":"43","author":"Mercier","year":"2018","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.ijpharm.2023.123252_b0255","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1021\/acs.molpharmaceut.8b00087","article-title":"Pharmacological characterization of the RPMI 2650 model as a relevant tool for assessing the permeability of intranasal drugs","volume":"15","author":"Mercier","year":"2018","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ijpharm.2023.123252_b0260","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2105-7-123","article-title":"Detecting outliers when fitting data with nonlinear regression - A new method based on robust nonlinear regression and the false discovery rate","volume":"7","author":"Motulsky","year":"2006","journal-title":"BMC Bioinf."},{"key":"10.1016\/j.ijpharm.2023.123252_b0265","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.ijpharm.2015.09.035","article-title":"Evaluation of the appropriate time range for estimating the apparent permeability coefficient (Papp) in a transcellular transport study","volume":"495","author":"Ozeki","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2023.123252_b0270","doi-asserted-by":"crossref","first-page":"288","DOI":"10.18433\/J3NC79","article-title":"Intranasal drug delivery: how, why and what for?","volume":"12","author":"Pires","year":"2009","journal-title":"J. Pharm. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2023.123252_b0275","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1080\/03639045.2017.1321659","article-title":"Development of a Soluplus budesonide freeze-dried powder for nasal drug delivery","volume":"43","author":"Pozzoli","year":"2017","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ijpharm.2023.123252_b0280","unstructured":"PubChem database. https:\/\/pubchem.ncbi.nlm.nih.gov\/."},{"key":"10.1016\/j.ijpharm.2023.123252_b0285","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1111\/j.1365-2125.2010.03757.x","article-title":"Acceptability and characteristics of 124 human bioequivalence studies with active substances classified according to the Biopharmaceutic Classification System","volume":"70","author":"Ramirez","year":"2010","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ijpharm.2023.123252_b0290","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1111\/j.2042-7158.2012.01540.x","article-title":"Cultivation of RPMI 2650 cells as an in-vitro model for human transmucosal nasal drug absorption studies: optimization of selected culture conditions","volume":"64","author":"Reichl","year":"2012","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ijpharm.2023.123252_b0295","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S0022-2275(20)38308-5","article-title":"Characterization of the total lipid and fatty acid composition of rat olfactory mucosa","volume":"30","author":"Russell","year":"1989","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.ijpharm.2023.123252_b0300","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ijpharm.2019.02.026","article-title":"How to characterize a nasal product. the state of the art of in vitro and ex vivo specific methods","volume":"561","author":"Salade","year":"2019","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2023.123252_b0305","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1258\/0022215001905508","article-title":"Study of surfactant level in cases of primary atrophic rhinitis","volume":"114","author":"Sayed","year":"2000","journal-title":"J. Laryngol. Otol."},{"key":"10.1016\/j.ijpharm.2023.123252_b0310","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1080\/10717544.2019.1704940","article-title":"Mechanisms of increased bioavailability through amorphous solid dispersions: a review","volume":"27","author":"Schittny","year":"2020","journal-title":"Drug Deliv."},{"key":"10.1016\/j.ijpharm.2023.123252_b0315","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ejps.2006.04.012","article-title":"Lipid composition effect on permeability across PAMPA","volume":"29","author":"Seo","year":"2006","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2023.123252_b0320","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ejpb.2019.10.008","article-title":"Suitability of RPMI 2650 cell models for nasal drug permeability prediction","volume":"145","author":"Sibinovska","year":"2019","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ijpharm.2023.123252_b0325","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ijpharm.2013.05.040","article-title":"Mucus as a barrier to lipophilic drugs","volume":"453","author":"Sigurdsson","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2023.123252_b0330","first-page":"3358","article-title":"Encapsulated escitalopram and paroxetine intranasal co-administration","volume":"12","author":"Silva","year":"2021","journal-title":"In Vitro\/In Vivo Evaluation. Front Pharmacol"},{"key":"10.1016\/j.ijpharm.2023.123252_b0335","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ejpb.2023.01.013","article-title":"Air-liquid interface (ALI) impact on different respiratory cell cultures","volume":"184","author":"Silva","year":"2023","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ijpharm.2023.123252_b0340","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.ejps.2012.01.011","article-title":"Skin-PAMPA: a new method for fast prediction of skin penetration","volume":"45","author":"Sink\u00f3","year":"2012","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2023.123252_b0345","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1016\/j.progpolymsci.2014.07.010","article-title":"Mucoadhesive polymers in the design of nano-drug delivery systems for administration by non-parenteral routes: a review","volume":"39","author":"Sosnik","year":"2014","journal-title":"Prog. Polym. Sci."},{"key":"10.1016\/j.ijpharm.2023.123252_b0350","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.ejps.2017.09.027","article-title":"Opportunity and challenges of nasal powders: drug formulation and delivery","volume":"113","author":"Tiozzo Fasiolo","year":"2018","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2023.123252_b0355","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1016\/j.addr.2005.07.009","article-title":"Nasal mucoadhesive drug delivery: background, applications, trends and future perspectives","volume":"57","author":"Ugwoke","year":"2005","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ijpharm.2023.123252_b0360","doi-asserted-by":"crossref","unstructured":"Vig, B. Morgen, M. Formulation, Process Development, and Scale-Up: Spray-Drying Amorphous Solid Dispersions for Insoluble Drugs. in Developing Solid Oral Dosage Forms 793\u2013820 (Academic Press, 2017). doi:10.1016\/B978-0-12-802447-8.00030-3.","DOI":"10.1016\/B978-0-12-802447-8.00030-3"},{"key":"10.1016\/j.ijpharm.2023.123252_b0365","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ejpb.2020.04.011","article-title":"QbD-driven development of intranasal lipid nanoparticles for depression treatment","volume":"153","author":"Vitorino","year":"2020","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ijpharm.2023.123252_b0370","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1016\/j.drudis.2019.06.001","article-title":"Antidepressants and nose-to-brain delivery: drivers, restraints, opportunities and challenges","volume":"24","author":"Vitorino","year":"2019","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ijpharm.2023.123252_b0375","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0928-0987(02)00240-3","article-title":"Permeability of porcine nasal mucosa correlated with human nasal absorption","volume":"18","author":"Wadell","year":"2003","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2023.123252_b0380","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.ejpb.2009.08.008","article-title":"RPMI 2650 epithelial model and three-dimensional reconstructed human nasal mucosa as in vitro models for nasal permeation studies","volume":"74","author":"Wengst","year":"2010","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ijpharm.2023.123252_b0385","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2020.626882","article-title":"Design and application in delivery system of intranasal antidepressants","volume":"8","author":"Xu","year":"2020","journal-title":"Front. Bioeng. Biotechnol."}],"container-title":["International Journal of Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378517323006725?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378517323006725?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T05:37:08Z","timestamp":1736401028000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378517323006725"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":77,"alternative-id":["S0378517323006725"],"URL":"https:\/\/doi.org\/10.1016\/j.ijpharm.2023.123252","relation":{},"ISSN":["0378-5173"],"issn-type":[{"value":"0378-5173","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nasal-PAMPA: A novel non-cell-based high throughput screening assay for prediction of nasal drug permeability","name":"articletitle","label":"Article Title"},{"value":"International Journal of Pharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijpharm.2023.123252","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"123252"}}